Study #2021-0400
A Phase II Study of Lenvatinib Plus Everolimus Versus Cabozantinib In Patients with Metastatic Renal Cell Carcinoma That Progressed on A PD-1/PD-L1 Checkpoint Inhibitor
MD Anderson Study Status
Not Accepting
Treatment Agent
Everolimus, Lenvatinib, Cabozantinib
Description
This phase II trial compares the effects of lenvatinib given in combination with everolimus to the effects of cabozantinib given alone in treating patients with renal cell cancer (RCC) that has spread to other parts of the body (metastatic) and that got worse on a previous PD-1/PD-L1 checkpoint inhibitor. Lenvatinib, everolimus, and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC V8, Stage IV Renal Cell Cancer AJCC V8
Study phase:
Phase II
Physician name:
Andrew Hahn
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-943-5165
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.